TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Geriatrician Nathaniel Chin says persistent concerns about memory or thinking can warrant a thorough assessment even when cognitive test scores remain in the normal range. Subjective cognitive decline is not a diagnosis of Alzheimer’s, and symptoms can have other causes; the source describes baseline and repeat testing, evaluation for contributing factors, and biomarkers for selected patients as parts of further assessment.
Geriatrician Nathaniel Chin argues that people who persistently notice changes in memory or thinking should receive a careful evaluation even when cognitive testing falls within the normal range. In a commentary published by Being Patient on October 27, 2026, he describes subjective cognitive decline as a possible opportunity to assess risk and address other causes—not as proof that a person has Alzheimer’s disease.
Subjective cognitive decline (SCD) refers to a person’s persistent sense that their cognitive abilities have worsened compared with their own earlier level, while comprehensive testing does not show objective impairment. Chin says that distinction can be missed when people are judged only by whether they fall below a population-based threshold. Someone whose abilities were once well above average, for example, could decline and still score in the average range.
He also distinguishes a brief screening from a comprehensive cognitive evaluation. Screenings commonly take five to 15 minutes and sample a limited range of abilities. A fuller evaluation generally takes an hour or more and examines areas such as memory, language, attention and executive function. Chin says establishing a detailed baseline and repeating assessments can help clinicians identify a consistent decline over time.
SCD has multiple possible explanations. Chin lists sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging as factors that can affect how clearly someone feels they are thinking. He recommends assessing these contributors and, when possible, seeking observations from someone who knows the person well. For selected patients, he says clinicians may also consider blood biomarkers, cerebrospinal fluid tests or amyloid PET to investigate whether Alzheimer’s-related biological changes are present.
Why Normal Scores May Not End the Review
The commentary highlights a potential gap between a person’s reported experience and a test result. A normal score means that measurable impairment has not been found; it does not necessarily establish that a person’s abilities have remained unchanged from their personal baseline. This distinction may affect decisions about follow-up.
Chin recommends assessment without assuming a cause. Tracking changes over time and evaluating other possible contributors may help clinicians better understand a patient’s concerns. Persistent concerns can be discussed with a health professional, but they do not establish Alzheimer’s disease or predict that it will develop.
The source describes the period before objective impairment as a possible opportunity for prevention and treatment discussions. It does not report trial results or establish that any particular intervention prevents Alzheimer’s in people with SCD. The commentary’s clinical focus is that screening results should be considered alongside a person’s history, functioning and changes over time.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Blueair Blue Pure 211i Max Smart Air Purifier for Large Rooms
Oral-B iO Series 7 Rechargeable Electric Toothbrush with 2 Brush Heads and Charging Travel Case
As an affiliate, we earn on qualifying purchases.
How Clinicians Describe SCD Plus
Chin discusses the “SCD plus” concept developed by psychiatrist Frank Jessen and colleagues in the international Subjective Cognitive Decline Initiative. The features are intended to identify patterns that may make subjective decline more concerning for early Alzheimer’s. They include memory-focused complaints, onset within the past five years, onset at age 60 or older, worry about the change, persistence, seeking medical help and confirmation from someone who knows the person well.
These features are not diagnostic, and the commentary says none proves Alzheimer’s disease. Concern may rise when several appear together, but other explanations still need to be considered. Chin contrasts a long-standing, intermittent word-finding concern associated with poor sleep or stress with a more recent, persistent memory change noticed by both a person and their spouse. Both individuals could score normally, yet their histories would call for different clinical attention.
The article’s author is a physician who treats patients in memory care and studies Alzheimer’s risk, prevention and biomarkers at the University of Wisconsin–Madison. The piece is presented as a physician’s perspective, not as a report of a new clinical trial, formal guideline or research finding.
What SCD Can and Cannot Establish
SCD alone cannot identify the cause of a perceived change or confirm that Alzheimer’s biological changes are present. The source gives no estimate of how often people with SCD later develop Alzheimer’s, nor does it report results showing that testing or treatment at this stage improves outcomes. The listed SCD-plus features indicate reasons for closer attention, not a definitive prediction for an individual.
The commentary mentions blood biomarkers, cerebrospinal fluid testing and amyloid PET as options for selected patients, but does not specify which patients should receive them, how results should be interpreted in each case or what treatment would follow. A clinician’s assessment remains necessary, including consideration of other health and life factors.
Clinical Follow-Up and Testing
Chin’s proposed next steps are to document a thorough cognitive baseline, review possible contributors, seek input from a trusted observer when available and repeat testing to see whether changes persist. For selected patients, clinicians may discuss biomarker testing to check for Alzheimer’s-related biology. The commentary does not announce a new test, a scheduled study or a change in treatment guidance.
Anyone concerned about a continuing change in memory or thinking can raise it with a qualified health professional, who can decide whether an assessment is appropriate. What happens after that will depend on the person’s symptoms, medical history and examination; the article does not provide a single pathway that applies to everyone.
Key Questions
Does subjective cognitive decline mean someone has Alzheimer’s?
No. SCD describes a persistent perceived change despite no objective impairment on comprehensive testing. It does not identify the cause or confirm Alzheimer’s disease.
Can a normal cognitive test miss a meaningful change?
It can fail to show a decline from a person’s own earlier abilities, Chin says, because results are often compared with people of similar age. A detailed baseline and repeat testing may help clinicians track change over time.
What is meant by SCD plus?
It is a set of features associated with greater concern, including recent and persistent memory complaints, worry about the change and confirmation by someone close to the person. These features do not prove Alzheimer’s.
What else can make thinking feel worse?
Chin lists sleep problems, medications, depression or anxiety, medical illness, vascular disease, hearing loss, stress and normal aging among possible contributors. A health professional can assess an individual’s situation.
What tests may be considered beyond cognitive assessments?
For selected patients, Chin says clinicians may consider blood biomarkers, cerebrospinal fluid testing or amyloid PET. The commentary does not set out a universal testing rule; decisions depend on clinical evaluation.
Source: beingpatient.com
